Modelling the daily risk of Ebola in the presence and absence of a potential vaccine

Ebola virus — one of the deadliest viral diseases, with a mortality rate around 90% — damages the immune system and organs, with symptoms including episodic fever, chills, malaise and myalgia. The Recombinant Vesicular Stomatitis Virus-based candidate vaccine (rVSV-ZEBOV) has demonstrated clinical e...

Full description

Bibliographic Details
Main Authors: Stéphanie M.C. Abo, Robert Smith?
Format: Article
Language:English
Published: KeAi Communications Co., Ltd. 2020-01-01
Series:Infectious Disease Modelling
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2468042720300579
_version_ 1797204015766831104
author Stéphanie M.C. Abo
Robert Smith?
author_facet Stéphanie M.C. Abo
Robert Smith?
author_sort Stéphanie M.C. Abo
collection DOAJ
description Ebola virus — one of the deadliest viral diseases, with a mortality rate around 90% — damages the immune system and organs, with symptoms including episodic fever, chills, malaise and myalgia. The Recombinant Vesicular Stomatitis Virus-based candidate vaccine (rVSV-ZEBOV) has demonstrated clinical efficacy against Ebola in ring-vaccination clinical trials. In order to evaluate the potential effect of this candidate vaccine, we developed risk equations for the daily risk of Ebola infection both currently and after vaccination. The risk equations account for the basic transmission probability of Ebola and the lowered risk due to various protection protocols: vaccination, hazmat suits, reduced contact with the infected living and dead bodies. Parameter space was sampled using Latin Hypercube Sampling, a statistical method for generating a near-random sample of parameter values. We found that at a high transmission rate of Ebola (i.e., if the transmission rate is greater than 90%), a large fraction of the population must be vaccinated (>80%) to achieve a 50% decrease in the daily risk of infection. If a vaccine is introduced, it must have at least 50% efficacy, and almost everyone in the affected areas must receive it to effectively control outbreaks of Ebola. These results indicate that a low-efficacy Ebola vaccine runs the risk of having vaccinated people be overconfident in a weak vaccine and hence the possibility that the vaccine could make the situation worse, unless the population can be sufficiently educated about the necessity for high vaccine uptake.
first_indexed 2024-04-24T08:28:31Z
format Article
id doaj.art-dea9d972196f418cb4d26af4cacb552d
institution Directory Open Access Journal
issn 2468-0427
language English
last_indexed 2024-04-24T08:28:31Z
publishDate 2020-01-01
publisher KeAi Communications Co., Ltd.
record_format Article
series Infectious Disease Modelling
spelling doaj.art-dea9d972196f418cb4d26af4cacb552d2024-04-16T20:57:50ZengKeAi Communications Co., Ltd.Infectious Disease Modelling2468-04272020-01-015905917Modelling the daily risk of Ebola in the presence and absence of a potential vaccineStéphanie M.C. Abo0Robert Smith?1Department of Applied Mathematics, The University of Waterloo, Waterloo, CanadaDepartment of Mathematics and Faculty of Medicine, The University of Ottawa, 150 Louis-Pasteur Pvt, Ottawa, ON, K1N6N5, Canada; Corresponding author.Ebola virus — one of the deadliest viral diseases, with a mortality rate around 90% — damages the immune system and organs, with symptoms including episodic fever, chills, malaise and myalgia. The Recombinant Vesicular Stomatitis Virus-based candidate vaccine (rVSV-ZEBOV) has demonstrated clinical efficacy against Ebola in ring-vaccination clinical trials. In order to evaluate the potential effect of this candidate vaccine, we developed risk equations for the daily risk of Ebola infection both currently and after vaccination. The risk equations account for the basic transmission probability of Ebola and the lowered risk due to various protection protocols: vaccination, hazmat suits, reduced contact with the infected living and dead bodies. Parameter space was sampled using Latin Hypercube Sampling, a statistical method for generating a near-random sample of parameter values. We found that at a high transmission rate of Ebola (i.e., if the transmission rate is greater than 90%), a large fraction of the population must be vaccinated (>80%) to achieve a 50% decrease in the daily risk of infection. If a vaccine is introduced, it must have at least 50% efficacy, and almost everyone in the affected areas must receive it to effectively control outbreaks of Ebola. These results indicate that a low-efficacy Ebola vaccine runs the risk of having vaccinated people be overconfident in a weak vaccine and hence the possibility that the vaccine could make the situation worse, unless the population can be sufficiently educated about the necessity for high vaccine uptake.http://www.sciencedirect.com/science/article/pii/S2468042720300579Ebola virus diseaseMathematical modelRisk equationsLatin hypercube samplingEradication
spellingShingle Stéphanie M.C. Abo
Robert Smith?
Modelling the daily risk of Ebola in the presence and absence of a potential vaccine
Infectious Disease Modelling
Ebola virus disease
Mathematical model
Risk equations
Latin hypercube sampling
Eradication
title Modelling the daily risk of Ebola in the presence and absence of a potential vaccine
title_full Modelling the daily risk of Ebola in the presence and absence of a potential vaccine
title_fullStr Modelling the daily risk of Ebola in the presence and absence of a potential vaccine
title_full_unstemmed Modelling the daily risk of Ebola in the presence and absence of a potential vaccine
title_short Modelling the daily risk of Ebola in the presence and absence of a potential vaccine
title_sort modelling the daily risk of ebola in the presence and absence of a potential vaccine
topic Ebola virus disease
Mathematical model
Risk equations
Latin hypercube sampling
Eradication
url http://www.sciencedirect.com/science/article/pii/S2468042720300579
work_keys_str_mv AT stephaniemcabo modellingthedailyriskofebolainthepresenceandabsenceofapotentialvaccine
AT robertsmith modellingthedailyriskofebolainthepresenceandabsenceofapotentialvaccine